key: cord-0717277-rfxf3zf8
authors: Casolla, Barbara; Cordonnier, Charlotte
title: Cerebral venous sinus thrombosis associated with COVID‐19 vaccine‐induced thrombocytopenia: Improvement in mortality rate over time
date: 2021-10-31
journal: Eur J Neurol
DOI: 10.1111/ene.15151
sha: bc132b11288b38d1ab41e1e7fb3bd0a213ee2a86
doc_id: 717277
cord_uid: rfxf3zf8

The clinical picture of moderate-to-severe thrombocytopenia and thrombotic complications at unusual sites occurring within 4 to 28 days of vaccination with the SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson) has been named vaccine-induced immune thrombotic thrombocytopenia (VITT) and several publications have followed the first case reports on March 28th , 2021 (1-5). The pathophysiology of VITT is not yet clearly understood.

Cerebral venous sinus thrombosis (CVST) is a rare and serious thrombotic complication, reported in about 70% of patients with VITT diagnosis [5, 6] . More than 90% of reported patients with CVST were younger than 60 years, with more women being affected than men (2.5:1 ratio) and no other specific identified risk factors [7] . The clinical profile of CVST in patients with VITT is severe, with about 70% of patients suffering intracerebral hemorrhages, 30% with coma at presentation, high rates of concomitant thromboembolism, and in-hospital death due to brain herniation occurring in approximately half of all patients [5] . Very early on, the international community took a multidisciplinary approach. Treatment of CVST with VITT has been empirical, and mainly based on our experience in the treatment of HIT. Prevention of thrombosis progression has relied on the use of nonheparin products such as argatroban, bivalirudin, danaparoid, fondaparinux, or direct oral anticoagulants at therapeutic anticoagulant dose, even in the presence of intracranial hemorrhages [7] .

Besides anticoagulation, intravenous immunoglobulins 1 g/kg body weight daily for 2 days were recommended, and platelet transfusion was contraindicated. Some expert recommendations also suggested the administration of steroids [7] . However, published data on the efficacy of this therapeutic strategy in patients with VITT are not yet available.

Munckof and colleagues compare acute mortality rates for CVST before versus after the first scientific publication on VITT, on 28

March, to evaluate whether outcome of patients with CVST-VITT improved over time [8] . 

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency

Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

Cerebral venous thrombosis

American Heart Association/American Stroke Association Stroke Council Leadership. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia

Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination